Clinical trial
A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma
NCT01015911 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma
- Lead sponsor
- Seagen Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2009
- Completion date
- March 31, 2012
- Enrollment
- 58 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.